Multiple Myeloma News


Here are all the latest news articles written by The Beacon's staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.


[ by | Dec 10, 2014 3:12 pm | 3 Comments ]
ASH 2014 Multiple Myeloma Update - Day Two: Education Session And Midday Oral Session

This past Sunday was the second day of the American Society of Hema­tology’s (ASH) annual meeting, which was held in San Francisco.

As on the first day of the meeting, myeloma-related pre­sen­ta­tions once again took place during several sessions throughout the day.

A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.

While the education session was being held, a separate “scientific sym­po­sium” with two oral pre­sen­ta­tions took place in parallel.  The session focused on a novel immunotherapeutic approach to treating cancer …

Read the full story »
[ by | Dec 8, 2014 7:02 am | 5 Comments ]
ASH 2014 Multiple Myeloma Update – Day One: Poster Session

Saturday was the official first day of the 2014 American Society of Hema­tology (ASH) annual meeting. The day featured a wide range of interesting pre­sen­ta­tions about multiple myeloma.

Oral presentations about new treatments under development were given mid-day and were summarized in a Beacon ASH Daily Update published yesterday morning.

During Saturday evening, a poster session took place where important new research findings were summarized in posters displayed throughout two separate large conference halls.

The studies covered a variety of myeloma-related topics, ranging from new treatments being developed for myeloma, …

Read the full story »
[ by | Dec 7, 2014 9:07 am | 3 Comments ]
ASH 2014 Multiple Myeloma Update - Day One: Oral Sessions

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in San Francisco.

Myeloma-related presentations were made during several sessions throughout the day.

The day started out with a session designed to better educate physicians about multiple myeloma and how to treat the disease.

Two sessions of oral presentations devoted solely to multiple myeloma ran simultaneously in the middle of the day. One of the sessions focused on the biology of the disease. The other one included presentations on new myeloma therapies for both newly diagnosed and …

Read the full story »
[ by | Dec 5, 2014 7:41 am | 4 Comments ]
ASH 2014 Preview: New Multiple Myeloma Treatments On The Horizon

The 2014 annual meeting of the American Society of Hematology (ASH) starts tomorrow, December 5, in San Francisco, and will continue until next Tuesday.

The ASH annual meeting is one of several large medical conferences where myeloma-related research findings are presented each year.  However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.

At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place.  The presentations will summarize current research on a wide range of topics, including the biology of …

Read the full story »
[ by | Nov 25, 2014 3:02 pm | One Comment ]
FDA Postpones Decision On Panobinostat Approval Application

The U.S. Food and Drug Administration (FDA) has postponed for up to three months its decision on pano­bino­stat’s new drug application.

The FDA action was announced earlier this morning in a press release issued by Novartis (NYSE:NVS), the Swiss pharmaceutical company developing pano­bino­stat as a potential new multiple myeloma therapy.

A decision on pano­bino­stat’s application for FDA approval had been expected by the end of this week. The decision was widely anticipated to be a negative one, given that earlier this month the FDA’s Oncologic Drugs Advisory …

Read the full story »
[ by | Nov 6, 2014 5:18 pm | One Comment ]
Panobinostat Fails In Bid For FDA Advisory Committee Support

Panobinostat had an important appointment this morning with a group of on­col­o­gists.

The appointment did not go so well.

The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) conducted a four-hour review of panobinostat (Farydak) earlier today.

At the end of the meeting, members of the committee were asked to vote whether they felt the benefits of panobinostat as a potential treatment for relapsed myeloma outweighed its risks.

Five committee members voted "no." Only two members voted "yes."

The advisory committee's vote is …

Read the full story »